Epigenetic determinants of healthy and diseased brain aging and cognition

JAMA Neurology

Volumn 70, Issue 6, 2013, Pages 711-718

  Akbarian, Schahram ^a   Beeri, Michal Schnaider ^a   Haroutunian, Vahram ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; GENOMIC DNA;

AGED; AMINO ACID SEQUENCE; ANXIETY; BRAIN DISEASE; CELL CYCLE; CHROMATIN STRUCTURE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DEVELOPED COUNTRY; DNA METHYLATION; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENOME ANALYSIS; HEREDITY; HISTONE MODIFICATION; HUMAN; INCIDENCE; LIFE EXPECTANCY; MENTAL DISEASE; MORTALITY; PRENATAL DEVELOPMENT; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW;

EID: 84878798054     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.1459     Document Type: Review

References (92)

1. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374(9696):1196-1208.
2. Centers for Disease Control and Prevention National Center for Health Statistics. National Vital Statistics Report. Hyattsville, MD: Centers for Disease Control and Prevention; 2004:53.
3. Börjesson-Hanson A, Gustafson D, Skoog I. Five-year mortality in relation to dementia and cognitive function in 95-year-olds. Neurology. 2007;69(22):2069-2075. (Pubitemid 350175709)
4. Skoog I. Psychiatric disorders in the elderly. Can J Psychiatry. 2011;56(7):387-397.
5. Barzilai N, Guarente L, Kirkwood TB, Partridge L, Rando TA, Slagboom PE. The place of genetics in ageing research. Nat Rev Genet. 2012;13(8):589-594.
6. Christensen K, Johnson TE, Vaupel JW. The quest for genetic determinants of human longevity: challenges and insights. Nat Rev Genet. 2006;7(6):436-448. (Pubitemid 43780487)
7. Gurland BJ, Page WF, Plassman BL. A twin study of the genetic contribution to age-related functional impairment. J Gerontol A Biol Sci Med Sci. 2004;59(8):859-863. (Pubitemid 39167432)
8. Ferri CP, Prince M, Brayne C, et al Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112-2117. (Pubitemid 41797645)
9. Corrada MM, Brookmeyer R, Berlau D, Paganini-Hill A, Kawas CH. Prevalence of dementia after age 90: results from the 90+ study. Neurology. 2008;71(5):337-343.
10. Holliday R. Epigenetics: a historical overview. Epigenetics. 2006;1(2):76-80.
11. Belmont AS. Mitotic chromosome structure and condensation. Curr Opin Cell Biol. 2006;18(6):632-638. (Pubitemid 44711888)
12. Tan M, Luo H, Lee S, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell. 2011;146(6):1016-1028.
13. Akbarian S, Huang HS. Epigenetic regulation in human brain-focus on histone lysine methylation. Biol Psychiatry. 2009;65(3):198-203.
14. Shen Y, Yue F, McCleary DF, et al. A map of the cis-regulatory sequences in the mouse genome. Nature. 2012;488(7409):116-120.
15. Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet. 2011;12(1):7-18.
16. Khare T, Pai S, Koncevicius K, et al. 5-hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. Nat Struct Mol Biol. 2012;19(10):1037-1043.
17. Fischer A, Sananbenesi F, Mungenast A, Tsai LH. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci. 2010;31(12):605-617.
18. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009;8(9):724-732.
19. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol. 2007;14(11):1025-1040. (Pubitemid 350060344)
20. Ho L, Crabtree GR. Chromatin remodelling during development. Nature. 2010;463(7280):474-484.
21. Fuentes P, Cánovas J, Berndt FA, Noctor SC, Kukuljan M. CoREST/LSD1 control the development of pyramidal cortical neurons. Cereb Cortex. 2011;22(6):1431-1441.
22. Hansen RS, Wijmenga C, Luo P, et al. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci U S A. 1999;96(25):14412-14417. (Pubitemid 30000664)
23. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99(3):247-257. (Pubitemid 29519904)
24. Klein CJ, Botuyan MV, Wu Y, et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet. 2011;43(6):595-600.
25. Winkelmann J, Lin L, Schormair B, et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum Mol Genet. 2012;21(10):2205-2210.
26. Kleefstra T, van Zelst-Stams WA, Nillesen WM, et al. Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype. J Med Genet. 2009;46(9):598-606.
27. Kirov G, Pocklington AJ, Holmans P, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry. 2012;17(2):142-153.
28. Verhoeven WM, Egger JI, Vermeulen K, van de Warrenburg BP, Kleefstra T. Kleefstra syndrome in three adult patients: further delineation of the behavioral and neurological phenotype shows aspects of a neurodegenerative course. Am J Med Genet A. 2011;155A(10):2409-2415.
29. O'Sullivan RJ, Karlseder J. The great unravelling: chromatin as a modulator of the aging process. Trends Biochem Sci. 2012;37(11):466-476.
30. Lu T, Pan Y, Kao SY, et al. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429(6994):883-891. (Pubitemid 38843301)
31. Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell. 2011;145(3):423-434.
32. Bhutani N, Burns DM, Blau HM. DNA demethylation dynamics. Cell. 2011;146(6):866-872.
33. Siegmund KD, Connor CM, Campan M, et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One. 2007;2(9):e895.
34. Hernandez DG, Nalls MA, Gibbs JR, et al. Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet. 2011;20(6):1164-1172.
35. Numata S, Ye T, Hyde TM, et al. DNA methylation signatures in development and aging of the human prefrontal cortex. Am J Hum Genet. 2012;90(2):260-272.
36. Tang B, Dean B, Thomas EA. Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders. Transl Psychiatry. 2011;1:e64.
37. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One. 2008;3(7):e2698.
38. Bakulski KM, Dolinoy DC, Sartor MA, et al. Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis. 2012;29(3):571-588.
39. Coppieters N, Dragunow M. Epigenetics in Alzheimer's disease: a focus on DNA modifications. Curr Pharm Des. 2011;17(31):3398-3412.
40. Desplats P, Spencer B, Coffee E, et al. Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J Biol Chem. 2011;286(11):9031-9037.
41. Walker MP, Laferla FM, Oddo SS, Brewer GJ. Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease [published online January 12, 2012]. Age (Dordr). doi:10.1007/s11357-011-9375-5.
42. Wang CM, Tsai SN, Yew TW, Kwan YW, Ngai SM. Identification of histone methylation multiplicities patterns in the brain of senescence-accelerated prone mouse 8. Biogerontology. 2010;11(1):87-102.
43. Peleg S, Sananbenesi F, Zovoilis A, et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science. 2010;328(5979):753-756.
44. Hargreaves DC, Horng T, Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell. 2009;138(1):129-145.
45. Copray S, Huynh JL, Sher F, Casaccia-Bonnefil P, Boddeke E. Epigenetic mechanisms facilitating oligodendrocyte development, maturation, and aging. Glia. 2009;57(15):1579-1587.
46. Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol. 2008;3:41-66. (Pubitemid 351488276)
47. Tang B, Chang WL, Lanigan CM, Dean B, Sutcliffe JG, Thomas EA. Normal human aging and early-stage schizophrenia share common molecular profiles. Aging Cell. 2009;8(3):339-342.
48. Nowrangi MA, Rao V, Lyketsos CG. Epidemiology, assessment, and treatment of dementia. Psychiatr Clin North Am. 2011;34(2):275-294, vii.
49. Gorelick PB, Scuteri A, Black SE, et al American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-2713.
50. Corrada MM, Berlau DJ, Kawas CH. A population-based clinicopathological study in the oldest-old: the 90+ study. Curr Alzheimer Res. 2012;9(6):709-717.
51. James BD, Bennett DA, Boyle PA, Leurgans S, Schneider JA. Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA. 2012;307(17):1798-1800.
52. Katsel P, Tan W, Haroutunian V. Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One. 2009;4(10):e7642.
53. Casanova MF, Starkstein SE, Jellinger KA. Clinicopathological correlates of behavioral and psychological symptoms of dementia. Acta Neuropathol. 2011;122(2):117-135.
54. Renthal W, Maze I, Krishnan V, et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron. 2007;56(3):517-529. (Pubitemid 350030878)
55. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006;9(4):519-525.
56. Jia H, Pallos J, Jacques V, et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis. 2012;46(2):351-361.
57. Lin YY, Kiihl S, Suhail Y, et al. Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK. Nature. 2012;482(7384):251-255.
58. Shimazu T, Horinouchi S, Yoshida M. Multiple histone deacetylases and the CREB-binding protein regulate pre-mRNA 3′-end processing. J Biol Chem. 2007;282(7):4470-4478. (Pubitemid 47100930)
59. Reichert N, Choukrallah MA, Matthias P. Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci. 2012;69(13):2173-2187.
60. Bahari-Javan S, Maddalena A, Kerimoglu C, et al. HDAC1 regulates fear extinction in mice. J Neurosci. 2012;32(15):5062-5073.
61. Park SW, Huq MD, Loh HH, Wei LN. Retinoic acid-induced chromatin remodeling of mouse kappa opioid receptor gene. J Neurosci. 2005;25(13):3350- 3357. (Pubitemid 40471343)
62. Ramamurthy S, Ronnett G. AMP-activated protein kinase (AMPK) and energy-sensing in the brain. Exp Neurobiol. 2012;21(2):52-60.
63. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32(11):591-601.
64. Baltan S, Murphy SP, Danilov CA, Bachleda A, Morrison RS. Histone deacetylase inhibitors preserve white matter structure and function during ischemia by conserving ATP and reducing excitotoxicity. J Neurosci. 2011;31(11):3990-3999.
65. Tsou AY, Friedman LS, Wilson RB, Lynch DR. Pharmacotherapy for Friedreich ataxia. CNS Drugs. 2009;23(3):213-223.
66. Morris MJ, Karra AS, Monteggia LM. Histone deacetylases govern cellular mechanisms underlying behavioral and synaptic plasticity in the developing and adult brain. Behav Pharmacol. 2010;21(5-6):409-419.
67. Covington HE III, Maze I, LaPlant QC, et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci. 2009;29(37):11451-11460.
68. Schroeder FA, Lin CL, Crusio WE, Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry. 2007;62(1):55-64. (Pubitemid 46898220)
69. Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci. 2009;30(2):55-60.
70. Kim SY, Levenson JM, Korsmeyer S, Sweatt JD, Schumacher A. Developmental regulation of Eed complex composition governs a switch in global histone modification in brain. J Biol Chem. 2007;282(13):9962-9972. (Pubitemid 47104642)
71. Gupta S, Kim SY, Artis S, et al. Histone methylation regulates memory formation. J Neurosci. 2010;30(10):3589-3599.
72. Huang HS, Matevossian A, Whittle C, et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci. 2007;27(42):11254-11262. (Pubitemid 47621326)
73. Kubicek S, O'Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007;25(3):473-481. (Pubitemid 46206139)
74. Maze I, Covington HE III, Dietz DM, et al. Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science. 2010;327(5962):213-216.
75. Jiang Y, Jakovcevski M, Bharadwaj R, et al. Setdb1 histone methyltransferase regulates mood-related behaviors and expression of the NMDA receptor subunit NR2B. J Neurosci. 2010;30(21):7152-7167.
76. Motta M, Bennati E, Ferlito L, Malaguarnera M, Motta L; Italian Multicenter Study on Centenarians (IMUSCE). Successful aging in centenarians: myths and reality. Arch Gerontol Geriatr. 2005;40(3):241-251. (Pubitemid 40462246)
77. Jefferson AL, Himali JJ, Au R, et al. Relation of left ventricular ejection fraction to cognitive aging (from the Framingham Heart Study). Am J Cardiol. 2011;108(9):1346-1351.
78. Beeri MS, Schmeidler J, Haroutunian V, et al. Better cognitive performance associated with worse cardiac functioning suggests antagonistic pleiotropy in very elderly subjects. Am J Geriatr Psychiatry. 2009;17(10):911-912.
79. Huang J, Schmeidler J, Beeri MS, et al. Haemoglobin A(1c) and cognitive function in very old, cognitively intact men. Age Ageing. 2012;41(1):125-128.
80. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49(21):2129-2138. (Pubitemid 46783865)
81. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002;52(2):168-174. (Pubitemid 34810596)
82. Silverman JM, Schmeidler J, Beeri MS, et al. C-reactive protein and familial risk for dementia: a phenotype for successful cognitive aging. Neurology. 2012;79(11):1116-1123.
83. Silverman JM, Beeri MS, Schmeidler J, et al. C-reactive protein andmemory function suggest antagonistic pleiotropy in very old nondemented subjects. Age Ageing. 2009;38(2):237-241.
84. Huffman DM, Deelen J, Ye K, et al. Distinguishing between longevity and buffered-deleterious genotypes for exceptional human longevity: the case of the MTP gene. J Gerontol A Biol Sci Med Sci. 2012;67(11):1153-1160.
85. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447-1451. (Pubitemid 32575406)
86. Schnaider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004;63(10):1902-1907. (Pubitemid 39532388)
87. Miech RA, Breitner JC, Zandi PP, Khachaturian AS, Anthony JC, Mayer L. Incidence of AD may decline in the early 90s for men, later for women: The Cache County Study. Neurology. 2002;58(2):209-218.
88. Zhang K, Schrag M, Crofton A, Trivedi R, Vinters H, Kirsch W. Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics. 2012;12(8):1261-1268.
89. Grünblatt E, Bartl J, Zehetmayer S, et al. Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J Alzheimers Dis. 2009;16(3):627-634.
90. Booij BB, Lindahl T, Wetterberg P, et al. A gene expression pattern in blood for the early detection of Alzheimer's disease. J Alzheimers Dis. 2011;23(1):109-119.
91. Horvath S, Zhang Y, Langfelder P, et al. Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol. 2012;13(10):R97.
92. Lambert JC, Mann D, Richard F, et al. Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2005;76(7):928-933. (Pubitemid 40916207)